Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06445036

Tunisian Clinical Registry on Hypoparathyroidism and Pseudo-hypoparathyroidism

Observational, multicenter, national, cross-sectional study aiming to describe the epidemiological clinical, biological and therapeutic profile of patients suffering from defect in secretion (hypoparathyroidism) or action (pseudo-hypoparathyroidism) of parathyroid hormone.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Hypoparathyroidism Bone Diseases Bone Diseases, Metabolic Calcium Metabolism Disorders Congenital, Hereditary, and Neonatal Diseases and Abnormalities Endocrine System Diseases Genetic Diseases, Inborn Metabolic Diseases Metabolism, Inborn Errors Metal Metabolism, Inborn Errors Musculoskeletal Diseases Nutritional and Metabolic Diseases Parathyroid Diseases Pseudo Hypoparathyroidism Pseudohypoparathyroidism

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Endocrinologists from both sectors (public and private) are participating in the study. Data will be captured electronically by DACIMA Clinical Suite, according to FDA 21 CFR part 11 (Food and Drug Administration 21 Code of Federal Regulations part 11), HIPAA (Health Insurance Portability and Accountability Act) & ICH (International Conference on Harmonisation) requirements.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hypoparathyroidism defined by low serum calcium < 2.2 mmol/l (< 88 mg/l) associated with inadequate PTH (low or normal) and normal creatinine

Exclusion criteria

  • Cervical surgery < 6 months.
  • Transient (neonatal, etc.) or functional (dysmagnesemia, etc.) hypoparathyroidism.
  • Other causes of hypocalcemia: vitamin D deficiency, chronic renal failure, etc.
  • Familial hypocalcemia hypercalciuria.
  • Pseudo-pseudo-hypoparathyroidism.

Treatment and study plan

Primary outcomes

  1. Incidence of primary hypoparathyroidism

    Time frame: Day 1

    Number of subjects with primary hypoparathyroidism at enrollment

  2. Incidence of congenital hypoparathyroidism

    Time frame: Day 1

    Number of subjects with congenital hypoparathyroidism at enrollment

  3. Incidence of acquired hypoparathyroidism

    Time frame: Day 1

    Number of subjects with acquired hypoparathyroidism at enrollment

  4. Incidence of secondary hypoparathyroidism

    Time frame: Day 1

    Number of subjects with secondary hypoparathyroidism at enrollment

Study contacts

Contact information is provided by the study sponsor or research team.

Nabila Rekik Mejdoub, MD

CONTACT

[email protected]

+216 98 609 300

Rabie Razgallah, MD

CONTACT

[email protected]

+216 20 509 729

Sponsors and collaborators

Lead sponsor

Dacima Consulting

Other

Collaborators

  • Société Tunisienne D'endocrinologie De Diabétologie Et Des Maladies Métaboliques

Registry information

Acronym: THYPARS

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jun 6, 2024
Registry last updated
Feb 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.